We are live on
!
Find out more
PVI
Pura Vida Investments Portfolio holdings
AUM
$37M
1-Year Est. Return
63.54%
This Fund
S&P 500
This Quarter
Est. Return
+16.35%
1 Year Est. Return
+63.54%
3 Year Est. Return
+38.32%
5 Year Est. Return
+47.02%
10 Year Est. Return
+2,091.28%
AUM
$239M
AUM Growth
-$323M
(-57%)
Cap. Flow
-$305M
Cap. Flow
% of AUM
-127.52%
Top 10 Holdings %
Top 10 Hldgs %
35.32%
Holding
126
New
39
Increased
3
Reduced
27
Closed
57
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$3.8M |
| 2 |
HCA Healthcare
HCA
|
+$3.62M |
| 3 |
HOLX
Hologic
HOLX
|
+$3.59M |
| 4 |
Medtronic
MDT
|
+$3M |
| 5 |
United Therapeutics
UTHR
|
+$2.66M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$19.8M |
| 2 |
LivaNova
LIVN
|
+$17.3M |
| 3 |
ICU Medical
ICUI
|
+$16.2M |
| 4 |
Centene
CNC
|
+$15.5M |
| 5 |
Boston Scientific
BSX
|
+$15.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 51.14% |
| 2 | Miscellaneous | 46.07% |
| 3 | Industrials | 2.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
OSI Systems
OSIS
$3.22B
| $13M | 5.43% |
+201,500
| New | +$16.9M |
|
|
2
CALL
LivaNova
LIVN
$4.33B
| $10.2M | 4.28% |
+128,000
| New | +$10.2M |
|
3
PUT
First Trust Health Care AlphaDEX Fund
FXH
$1.14B
| $9.07M | 3.8% |
130,000
+30,000
| +30% | +$2.05M |
|
4
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$43.5B
| $8.27M | 3.46% |
100,000
-100,000
| -50% | -$8.24M |
|
|
5
ICU Medical
ICUI
$3.89B
| $7.56M | 3.16% |
35,000
-80,000
| -70% | -$16.2M |
|
6
Globus Medical
GMED
$10.1B
| $7.5M | 3.14% |
182,500
-75,648
| -29% | -$2.65M |
|
7
PUT
State Street SPDR S&P Biotech ETF
XBI
$10.4B
| $7.43M | 3.11% |
87,500
-12,500
| -13% | -$1.05M |
|
8
PUT
iShares Russell 2000 ETF
IWM
$76.5B
| $7.24M | 3.03% |
47,500
-32,500
| -41% | -$4.88M |
|
|
9
LivaNova
LIVN
$4.33B
| $7.19M | 3.01% |
90,000
-218,546
| -71% | -$17.3M |
|
10
PUT
iShares Biotechnology ETF
IBB
$10.3B
| $6.94M | 2.9% |
65,000
+5,000
| +8% | +$534K |
|
|
ATHN
11
DELISTED
Athenahealth, Inc.
ATHN
| $6.65M | 2.78% |
50,000
-69,600
| -58% | -$8.89M |
|
12
Dentsply Sirona
XRAY
$2.02B
| $6.09M | 2.55% |
92,500
-227,500
| -71% | -$14.5M |
|
|
13
Boston Scientific
BSX
$63.6B
| $5.7M | 2.39% |
230,000
-550,000
| -71% | -$15.2M |
|
|
14
PUT
Boston Scientific
BSX
$63.6B
| $5.7M | 2.39% |
+230,000
| New | +$6.34M |
|
|
ZGNX
15
DELISTED
Zogenix, Inc.
ZGNX
| $5.22M | 2.18% |
130,268
+50,268
| +63% | +$1.93M |
|
|
MZOR
16
PUT
DELISTED
Mazor Robotics Ltd.
MZOR
| $4.76M | 1.99% |
+92,300
| New | +$5.19M |
|
17
PUT
Incyte
INCY
$25.3B
| $4.74M | 1.98% |
50,000
-50,000
| -50% | -$5.23M |
|
|
WBA
18
CALL
DELISTED
Walgreens Boots Alliance
WBA
| $4.72M | 1.97% |
65,000
-75,000
| -54% | -$5.28M |
|
|
IVC
19
DELISTED
Invacare Corporation
IVC
| $4.67M | 1.95% |
277,274
-722,726
| -72% | -$11.8M |
|
20
Abbott
ABT
$177B
| $4.57M | 1.91% |
80,000
-80,000
| -50% | -$4.43M |
|
21
PUT
Vanda Pharmaceuticals
VNDA
$302M
| $4.56M | 1.91% |
+300,000
| New | +$4.45M |
|
22
Baxter International
BAX
$12.2B
| $4.53M | 1.89% |
70,000
-200,000
| -74% | -$12.8M |
|
|
23
HCA Healthcare
HCA
$93.2B
| $3.95M | 1.65% |
+45,000
| New | +$3.62M |
|
|
24
BioMarin Pharmaceuticals
BMRN
$12.5B
| $3.9M | 1.63% |
+43,700
| New | +$3.8M |
|
|
HOLX
25
DELISTED
Hologic
HOLX
| $3.85M | 1.61% |
+90,000
| New | +$3.59M |
|
Similar funds
MAM
GSEP
CTC
XA
YEPI
PEP
CP
WTG
Pura Vida Investments's Q4 2017 Portfolio in Review
As of Q4 2017, Pura Vida Investments held 126 positions worth $239M, down 57% from $562M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Pura Vida Investments withdrew a net $305M in Q4 2017, closing 57 positions and reducing 27 holdings. Its most notable exit was Merck, an estimated $19.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 51% of assets, down from 72% a quarter earlier, followed by Miscellaneous and Industrials.
Against the trend, Pura Vida Investments opened a new position in BioMarin Pharmaceuticals worth $3.9M.
- Pura Vida Investments's largest Q4 2017 buy was BioMarin Pharmaceuticals: 43,700 shares worth $3.9M.
- Pura Vida Investments added most to Zogenix, Inc. in Q4 2017, an estimated $1.93M increase.
- Pura Vida Investments's biggest Q4 2017 reduction was LivaNova, cutting an estimated $17.3M.
- Pura Vida Investments fully exited Merck in Q4 2017, selling an estimated $19.8M.
- Pura Vida Investments's ten largest holdings make up 35% of its $239M portfolio in Q4 2017.
- Pura Vida Investments opened 39 new positions and closed 57 in Q4 2017.
- Pura Vida Investments's portfolio value fell 57% quarter-over-quarter to $239M.
Based on Pura Vida Investments's 13F filing for Q4 2017, filed 14 Feb 2018.